Objective. Provide a review and update of gefitinib (Iressa®), including recent data on mutations in the epidermal growth factor receptor (EGFR) and possible implications in non-small cell lung cancer patients.
Data sources. Primary literature and review articles were researched using Pub-Med. Articles through June 2004 were considered for preparation of the review. All clinical trials with published results and articles reporting EGFR mutations were considered for inclusion by the authors.
Conclusions. Gefitinib is a novel EGFR tyrosine kinase inhibitor approved for treatment of chemo-resistant NSCLC. Response rates of 10-19% have been observed in clinical trials with no improvement when combined with chemotherapy. Currently, gefitinib is used as a single agent for advanced NSCLC that is resistant to chemotherapy. Mutations in EGFR correlating with response to gefitinib have recently been described. Based on these early results, genetic testing of NSCLC patients upon diagnosis could predict response to gefitinib. Early treatment of NSCLC patients positive for EGFR mutations with gefitinib remains to be tested.
Herbst RS.Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys2003; 59: 21-26.
2.
Arteaga CL.ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res2003; 284: 122-130.
3.
Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ.Cancer statistics, 2004. CA Cancer J Clin2004; 54: 8-29.
4.
Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O’Connell M, Shepherd FA, Johnson BE.Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol2001; 19: 1734-1742.
5.
Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R.United States food and drug administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res2004; 10: 1212-1218.
6.
Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC.Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA2003; 290: 2149-2158.
7.
Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol2004; 22: 777-784.
8.
Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol2004; 22: 785-794.
9.
Schlessinger J.Cell signaling by receptor tyrosine kinases. Cell2000; 102: 211-225.
10.
Yarden Y, Sliwkowski MX.Untangling the ErbB signaling network. Nat Rev Mol Cell Biol2001; 2: 127-137.
11.
Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK.ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol2002; 20: 2240-2250.
12.
Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M.Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol2003; 14: 922-930.
13.
Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM.Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol2002; 20: 3815-3825.
14.
Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J.Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol2002; 20: 4292-4302.
15.
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol2003; 21: 2237-2246.
16.
Natale RB, Skarin A, Maddox A-M, Hammond LA, Thomas R, Gandara DR, Gerstein H, Panella TJ, Cole J, Jahanzeb M, Kash J, Hamm J, Langer CJ, Saleh M, Stella PJ, Heyes A, Helms L, Ochs J, Averbuch S, Wolf M, Kay A.Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (‘Iressa’) in IDEAL 2. Proc Am Soc Clin Oncol2002; 21: 292a-292a.
17.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Published online 29 April 2004; 10.1126/science.1099314. Retrieved from: http://www.sciencemag.org.
18.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med2004; 350: 1-11.
19.
Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH.ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res2002; 62: 5749-5754.
